modelRizatriptan
Extends from Pharmacolibrary.Drugs.ATC.N.N02CC04.
Information
| name: | Rizatriptan | |
| ATC code: | N02CC04 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 140 | L |
| clearance: | 41 | L/h |
| other parameters in model implementation | ||
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan class) used in the acute treatment of migraine attacks with or without aura in adults. It is approved and widely used today for this indication.
Pharmacokinetics
Healthy adult subjects, single-dose pharmacokinetics after oral administration.
References
Tellone, V, et al., & Wedemeyer, RS (2020). A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. International journal of clinical pharmacology and therapeutics 58(10) 583–594. DOI:10.5414/CP203652 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32716291
Fraser, IP, et al., & Winner, P (2012). Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache 52(4) 625–635. DOI:10.1111/j.1526-4610.2011.02069.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22289113
Eiland, LS, & Hunt, MO (2010). The use of triptans for pediatric migraines. Paediatric drugs 12(6) 379–389. DOI:10.2165/11532860-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21028917
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)